Among adults with cardiovascular disease and BMI ≥27kg/m < sup > 2 < /sup > but no diabetes, does semaglutide lower risk of cardiovascular mortality, myocardial infarction, or stroke when compared with placebo, and is it safe?

Rev Med Interne. 2024 Jan 15:S0248-8663(24)00007-9. doi: 10.1016/j.revmed.2024.01.006. Online ahead of print.NO ABSTRACTPMID:38228454 | DOI:10.1016/j.revmed.2024.01.006

Source: Revue de Medecine Interne - January 16, 2024 Category: Internal Medicine Authors: L Lanthier M-F Langlois M- É Plourde M Cauchon Source Type: research